U.S. markets closed
  • S&P 500

    4,473.75
    -6.95 (-0.16%)
     
  • Dow 30

    34,751.32
    -63.07 (-0.18%)
     
  • Nasdaq

    15,181.92
    +20.39 (+0.13%)
     
  • Russell 2000

    2,232.91
    -1.54 (-0.07%)
     
  • Crude Oil

    72.59
    -0.02 (-0.03%)
     
  • Gold

    1,753.80
    -2.90 (-0.17%)
     
  • Silver

    22.90
    +0.11 (+0.47%)
     
  • EUR/USD

    1.1770
    -0.0056 (-0.47%)
     
  • 10-Yr Bond

    1.3310
    +0.0270 (+2.07%)
     
  • GBP/USD

    1.3793
    -0.0042 (-0.30%)
     
  • USD/JPY

    109.7210
    +0.3610 (+0.33%)
     
  • BTC-USD

    47,667.68
    -442.20 (-0.92%)
     
  • CMC Crypto 200

    1,209.85
    -23.43 (-1.90%)
     
  • FTSE 100

    7,027.48
    +10.99 (+0.16%)
     
  • Nikkei 225

    30,323.34
    -188.37 (-0.62%)
     

AzurRx BioPharma To Acquire First Wave Bio For $229M

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments.

  • First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD).

  • In conjunction with the acquisition, AzurRx will change its name to First Wave BioPharma and trade on NASDAQ under the new ticker symbol, FWBI, effective by September 23.

  • In January, AzurRx in-licensed from First Wave Bio the exclusive global rights to develop two niclosamide therapeutic indications for COVID-19-related GI infections and immune checkpoint inhibitor-associated colitis and diarrhea (ICI-AC) in advanced-stage cancer patients.

  • Following the acquisition of First Wave Bio, AzurRx's internal development pipeline will include three new clinical IBD indications.

  • Last week, AzurRx BioPharma announced a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares.

  • Also Read: Why AzurRx Stock Is Trading Higher After MS1819 Combo Therapy Data?

  • Price Action: AZRX shares are trading at $5.16 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.